MedTrace Logo

Endoscopic Relapse Risks Evaluation After Ileocolic Resection for Crohn's Disease

NCT06299631 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 133

Last updated 2024-03-08

No results posted yet for this study

Summary

Aim of the study:

To evaluate risk factors of endoscopic relapse after ileocolic resection in a cohort of Crohn's disease patients treated with anti-TNF agents.

Methods:

From 2014 to 2022, all consecutive patients who underwent ileocolic resection for Crohn's disease treated with anti-TNF agents in two referral tertiary center were prospectively collected.

Considering exclusion criteria, data from 114 patients were analyzed. The cohort was separated into 2 groups according to study period.

Short and long-term outcomes were compared between the two groups.

Primary outcome:

Endoscopic recurrence (defined as \> i2 lesions according to Rutgeerts classification) 6 months after surgery

Conditions

Interventions

PROCEDURE

Ileocolic resection

Ileocolic resection by open or laparoscopic approach

Sponsors & Collaborators

  • Carémeau University Hospital, Nîmes

    collaborator UNKNOWN

  • University Hospital, Montpellier

    lead OTHER

Principal Investigators

  • Thomas BARDOL, MD, MSc · Montpellier University Hospital

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2023-06-30
Completion
2023-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06299631 on ClinicalTrials.gov